Souhaitez-vous accéder aux communiqués récents ?

Shire Provides Regulatory Progress Update for Key Pipeline Programs Targeting Rare Disease - U.S. FDA Grants Orphan Drug Designation for Investigational SHP647 for Treatment of Pediatric Patients...

Shire to Highlight Advancements in Diagnosis, Treatment and Management of Rare Lysosomal Diseases at Global Conference 12 presentations and three satellite symposia showcase Shire's commitment...

Shire to announce full year 2017 results Dublin, Ireland - February 1, 2018 - Shire plc (LSE: SHP, NASDAQ: SHPG), will announce full year 2017 earnings on Wednesday February 14, 2018. Results...

Total Voting Rights February 1, 2018 - Shire plc (LSE: SHP, NASDAQ: SHPG) (the "Company"), in accordance with 5.6.1R of the Financial Conduct Authority's (the "FCA") Disclosure Guidance and...

Shire presentations at EAHAD 2018 demonstrate commitment to studying outcomes in patients with bleeding disorders Shire presentations showcase heritage in Hematology Zug, Switzerland -...

AB Biosciences and Shire Enter Into Agreement for Development and Commercialization of AB Biosciences' PRIM Program for Potential Treatment of Autoimmune Diseases and Other Immune-Mediated Disorders ...

 FDA Grants Approval to Shire for Technology Transfer of CINRYZE® (C1 esterase inhibitor [human]) Drug Product Manufacturing Process to Vienna, Austria Manufacturing SiteSecond production source for...

Shire Continues to Uphold High Standards of Ethics and Transparency with Adoption of Open Access Policy for Publication of Shire-Supported Research Cambridge, MA - January 23, 2018 - Shire plc...

Shire to Present Data on Short Bowel Syndrome With Intestinal Failure at the ASPEN 2018 Nutrition Science & Practice Conference Cambridge, Mass. - January 22, 2018 -  Shire plc (LSE: SHP,...

Directorate Change Dublin, Ireland - January 19, 2018 - Shire plc (LSE: SHP, NASDAQ: SHPG) (the "Company") announces that Thomas Dittrich will assume his role as Chief Financial Officer, and become...